Recreational Therapy at Niagara Health - Niagara Health

ISLAMABAD, Oct. 25 (Xinhua) -- A 53-day-old infant died of mpox in Pakistan's southern Sindh province on Saturday, raising the death toll from the disease in the province to 12 this year, health officials said. The infant, a resident of Karachi's Malir district, was transferred to the Sindh Infectious Diseases Hospital and Research Center (SIDH&RC) after developing symptoms following a circumcision procedure at a private hospital, the facility's medical superintendent, Abdul Wahid Rajput, told local media. Rajput confirmed that mpox was the cause of death. The Sindh Healthcare Commission (SHCC) has sealed Ibn-e-Hassan Hospital in Malir, where the procedure was performed, after an investigation found inadequate infection prevention and control measures, poor hygiene and unqualified staff, according to an official statement. The commission said the infant contracted the virus through contaminated scissors used during the procedure. Laboratory testing confirmed the infection. Separately, the Sindh health department reported two more mpox cases on Friday, bringing the provincial tally to 98.

Two doses of preoperative durvalumab can rapidly transform the immune microenvironment of stage I triple-negative breast cancer, but immune activation alone rarely translates into complete tumor eradication. First results from the phase II UNLOCK 14–POP-DURVA trial, presented at ESMO Congress 2026, showed that short-course durvalumab monotherapy produced a pathologic complete response in only 1.4% of patients, while major pathologic response was observed in approximately 11%.

Proteins linked to the immune system, cell adhesion, blood vessel formation, and known prostate cancer genes, were associated with the future risk of developing prostate cancer, including aggressive disease, in a new study led by researchers at Oxford Population Health. The findings reveal biological differences between men who later developed prostate cancer and those who did not, and may help guide future studies aimed at identifying men at greater risk of the disease. The study, published in European Urology and presented at the American Society of Human Genetics (ASHG) Annual Meeting, is the largest population-based investigation to date of blood proteins and future prostate cancer risk, with a particular focus on aggressive disease. Prostate cancer is the most commonly diagnosed cancer in men worldwide, but relatively little is known about why some men develop the disease or why some cancers become aggressive. Most established risk factors, such as age and genetics, cannot be changed.